INHIBITOR OF S1P BINDING Russian patent published in 2012 - IPC C07D213/64 C07D213/68 C07D213/70 C07D239/34 C07D401/12 C07D405/12 C07D409/12 C07D417/12 A61K31/44 A61K31/4709 A61K31/4725 A61K31/496 A61K31/505 A61K31/5377 

FIELD: chemistry.

SUBSTANCE: compound, represented by formula

,

or its pharmaceutically acceptable salt, where Y¹ represents nitrogen atom or group, represented by CR^A, Y² represents nitrogen atom or group, represented by CR^B, Y³ represents nitrogen atom or group, represented by CR^C, R^A, R^B and R^C, which can be similar or different, each represents hydrogen atom, etc. (except in the case, when Y¹ is CR^A, Y² is CR^B and Y³ is CR^C), X represents oxygen atom, etc., R¹ represents C₁-C₆alkyl group, etc., R³ represents optionally substituted phenyl group, etc., R⁴ represents hydrogen atom, etc., and R⁵ represents optionally substituted phenyl group, etc.), possesses inhibiting action with respect to S1P binding with its receptor Edg-1(SlP₁).

EFFECT: obtaining composition, which can be used as therapeutic medication in case of autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis or age-related macula lutea degeneration, etc.

13 cl, 9 ex, 1 tbl, 4 dwg